Titel: Scaling-up of Biopharmaceutical Products

Termin: 26.1.2004, 8:00 Uhr, bis 27.1.2004, 18:00 Uhr

Veranstaltungsort:
Amsterdam Hilton
Apollolaan 138
NL 1077 BG Amstedam
The Netherlands

Referenten: see their page for more information

Weitere Informationen:
http://www.ibc-lifesci.com/scaleup/

Kurzbeschreibung: There are great pressures on your industry to accelerate the process development of a biopharmaceutical whilst simultaneously scaling up drug supply for clinical trials. Companies are keen to implement early strategies to ensure continuity of development and to avoid the need to rework process development.

This conference will focus on the transition of biopharmaceutical products from discovery to pre-clinical, to Phase I/II, Phase III, launch and commercial scale-up. The presentations will be case study driven and cover the relevant points of bioprocessing which are critical for clinical and commercial success to meet your economic targets.

This event will help you understand how others have succeeded in scaling-up their biologics in a timely fashion, while avoiding the common stumbling blocks that occur when scaling-up a manufacturing process.

The use of case studies within the conference programme will reveal how to...

* develop a successful biopharmaceutical manufacturing process and characterise the product for the clinic

* translate small scale synthesis to large scale manufacturing

* combat the regulatory issues associated with scale-up

* shrink development time and increase results

* decrease time to clinic and market

* develop a validatable manufacturing process that can be scaled up with minimal difficulty

* meet the requirements of reliability, quality and quantity of materials

Kontakt: Mrs Laura Beachus
The Booking Department
Informa Uk Limited
P.O. Box 406
KT 14 6NN West Byfleet
England

phone: +44 - 20 - 70 17 55 07
fax: +44 - 20 - 70 17 47 49

cust.serv@informa.com

Veranstalter: ibc Life Sciences

Wissenschaftliche Leitung: Dr Julio Baez, Senior Research Fellow, Fibrogen, USA, Professor John Birch, Chief Scientific Officer, Lonza Group, UK, Dr Richard Francis, Operations Support Manager, Protherics Ltd, UK, Dr Uwe Gottschalk, Head of GMP Protein Manufacturing, Bayer AG, Germany, Professor Florian M. Wurm, Swiss Federal Institute of Technology, Lausanne, Switzerland and Chief Scientific Officer, ExcellGene SA, Switzerland

Schlagworte: Pharmazeutik